Tufts University

University of Houston System

The Research Institute of Fox Chase Cancer Center

Sameer Nikhar

Gregory D Cuny

Alexei Degterev

Siddharth Balachandran

Gregory Cuny

Identified compounds demonstrate protein kinase inhibitory activity. More specifically, the compounds are demonstrated to inhibit receptor interacting kinase 2 (RIPK2) and/or Activin-like kinase 2 (ALK2). Compounds that are either dual RIPK2/ALK2 inhibitors or that preferentially inhibit RIPK2 or ALK2 could provide therapeutic benefit.

Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases

Identified compounds demonstrate protein kinase inhibitory activity. More specifically, the compounds having the structures below (I) are demonstrated to inhibit receptor interacting kinase 2 (RIPK2) and/or Activin-like kinase 2 (ALK2). Compounds that are either dual RIPK2/ALK2 inhibitors or that preferentially inhibit RIPK2 or ALK2 could provide therapeutic benefit. 

Growing community of inventors

Houston, TX, United States of America

Sameer Nikhar